Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by vascular involvement and the intensity of fibrosis. The lack of available treatment is largely due to the very fragmented understanding of the pathophysiology of SSc. However, one of the keys to conducting quality research on this disease remains the development of well-documented patient cohorts with reliable biological samples. The main objective of this cohort is to study the natural progression of SSc in a cohort of patients followed over 5 years.
Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by vascular involvement and the intensity of fibrosis. Its prevalence and incidence are difficult to assess, however, in France, a population survey conducted in Seine-St-Denis calculated a prevalence of 161 cases per million inhabitants. The pathophysiology of SSc, the exact etiology of which remains unknown, involves an interaction between genetic and environmental factors. Its evolution can impact the aesthetic, functional and even vital prognosis of the affected patient.Within the analysis of SSc pathophysiology, a " very early systemic sclerosis " form of disease has been defined according to the presence of Raynaud's phenomenon and auto-antibodies in blood sample (ACAN positivity (≥1/160) with anti-Scl70, anti-centromere or anti-ARNPolIII specificity). At present, no treatment to control this disease is available. The lack of available treatment is largely due to the very fragmented understanding of the pathophysiology of SSc. However, one of the keys to research remains the development of well-documented patient cohorts with quality biological samples. The investigators had the opportunity to start a major work on this plan with the VISS study (Vasculopathy and Inflammation in Systemic Scleroderma study) in 2012 as part of a project promoted by the University Hospital of Bordeaux (NCT02562079). This project has paved the way for many local, national and international collaborations. It has made it possible to structure and federate various partners of the Bordeaux University Hospital around translational research on SSc. The investigators wish to continue our research and collaborations by further strengthening our expertise in the collection of rare and valuable biological samples for this disease.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
500
62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Skin biopsies only for volunteers among patients
50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration only for volunteers among patients
Digestives biopsies if requires this type of exploration in the standard of care only for volunteers among patients
CHU de Bordeaux - service de rhumatologie
Bordeaux, France
RECRUITINGChange of the main clinical characteristics of scleroderma patients
Worsening of the SSc according to the onset of a renal crisis (according to arterial hypertension \> 150/85 mm Hg ), a pulmonary arterial hypertension (identified with a right heart catheterization), or an interstitial lung disease (identified with a chest CT-scan).
Time frame: At baseline (Day 0) and 60 months after baseline
Proportion of pulmonary arterial hypertension diagnosis in SSc patients
Time frame: At baseline (Day 0) and 60 months after baseline
Proportion of interstitial lung disease diagnosis in SSc patients
Time frame: At baseline (Day 0) and 60 months after baseline
Proportion of renal crisis diagnosis in SSc patients
Time frame: At baseline (Day 0) and 60 months after baseline
Mean of Rodnan score for the evaluation of disease activity for SSc patients, with higher values mean higher disease activity.
(Min value: 0 - Max value: 51)
Time frame: At baseline (Day 0) and 60 months after baseline
Mean of Diffusing capacity (DLCO) for the evaluation of disease activity for SSc patients
Time frame: At baseline (Day 0) and 60 months after baseline
Mean of Forced vital capacity (FVC) for the evaluation of disease activity for SSc patients
Time frame: At baseline (Day 0) and 60 months after baseline
Proportion of therapeutic strategies set up for SSc patients
Time frame: At baseline (Day 0) and 60 months after baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.